Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026
Basics
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Market cap
505.4B USD
Enterprise value
568.6B USD
Full-time employees
57,000
Overall health
Strength:growing faster than most peersgrowing faster than peers
Drawback:higher risk than most peers: less short-term liquidity (current ratio 0.81 vs a peer median of 2.59)higher risk: less liquidity (current ratio 0.81 vs peers 2.59)
About average: valuation
Ranks #552 of 1,157 healthcare companies (top 48%)
Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
AbbVie's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Stock pay is large next to buybacks. Stock-based pay expense $2.6B vs $4.7B spent repurchasing shares over the 3 fiscal years to 2025.
Over three fiscal years AbbVie recorded $2.6B of stock-based pay expense and spent $4.7B repurchasing shares (repurchases can include shares withheld to cover employees' taxes).Over three fiscal years AbbVie recorded $2.6B of stock-based pay expense and spent $4.7B repurchasing shares.
Sales growing faster than profits. Since 2022: revenue +5.4%, operating profit −17%.
Since 2022, AbbVie's revenue changed +5.4% while operating profit fell 17%: costs rose faster than sales.
Cash flow well above reported profit. Free cash flow is 2.9× reported profit.
Free cash flow is 2.9× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about AbbVie
Is AbbVie getting weaker?
Its latest SEC filing (Aug 3, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.
How is AbbVie valued vs its peers?
Priced about in line with its peers. Valuation scores 48/100 against 1,393 healthcare peers.
Is AbbVie growing?
Yes, faster than most of its peers. Growth scores 66/100 against 1,393 healthcare peers.Earnings per share growth 67.6% vs a peer median of 9.8% (stronger than 83% of peers).Earnings per share growth 67.6% vs peers 9.8% (stronger than 83% of peers).
How profitable is AbbVie?
More profitable than most of its peers. Profitability scores 87/100 against 1,393 healthcare peers.Operating margin 26.2% vs a peer median of 7.1% (stronger than 90% of peers).Operating margin 26.2% vs peers 7.1% (stronger than 90% of peers).
How risky is AbbVie?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 0.23 vs a peer median of 0.63 (stronger than 88% of peers).Beta 0.23 vs peers 0.63 (stronger than 88% of peers).Current ratio 0.81× vs a peer median of 2.59× (weaker than 95% of peers).Current ratio 0.81× vs peers 2.59× (weaker than 95% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 3, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
62.8B USD
64.4B USD
+2.5%
Net income (12 months)
3.6B USD
6.3B USD
+73.6%
Operating margin
24.4%
26.2%
+1.8 pts
Free cash flow (12 months)
20.0B USD
18.2B USD
−8.9%
Debt
72.9B USD
70.8B USD
−2.8%
Cash
9.4B USD
6.6B USD
−30.1%
Shares outstanding
1.77B
1.77B
+0.0%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Drug Manufacturers - General companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
69.0%
70.0%
62.4%
70.0%
70.2%
▲ 0.2 pts
Operating margin
31.9%
31.2%
23.5%
16.2%
24.6%
▲ 8.4 pts
Net margin
20.5%
20.4%
9.0%
7.6%
6.9%
▼ 0.7 pts
Return on assets (ROA)
7.9%
8.5%
3.6%
3.2%
3.2%
▼ 0.0 pts
Return on equity (ROE)
74.9%
68.6%
46.9%
128.7%
—
—
Free cash flow margin
39.1%
41.8%
40.6%
31.7%
29.1%
▼ 2.5 pts
Current ratio
0.79×
0.96×
0.87×
0.66×
0.67×
▲ 1.7%
Quick ratio
0.70×
0.84×
0.76×
0.55×
0.56×
▲ 0.8%
Debt to equity
4.98×
3.67×
5.73×
20.19×
—
—
Interest coverage
7.40×
8.12×
5.74×
3.25×
5.21×
▲ 60%
ABBV price history
Price history is added with the daily price update and will appear after the next one.